Canadian CBD-Focused Pharma Co. Gets Green Light To Produce Medical Marijuana In Brazil
Canadian CBD-Focused Pharma Co. Gets Green Light To Produce Medical Marijuana In Brazil
MediPharm Labs Corp. (TSX:LABS) (OTCQB:MEDIF) (FSE: MLZ) has received a GMP certification for its Barrie, Ontario facility from ANVISA, the governing body of Brazil's pharmaceutical industry.
MediPharm Labs Corp.（多倫多證券交易所股票代碼：LABS）（OTCQB: MIF）（FSE: MLZ）已獲得巴西製藥行業管理機構ANVISA頒發的安大略省巴里工廠的GMP認證。
This is MediPharm's latest approval, following GMP certifications from the FDA, European Union and Australia's TGA, MediPharm also holds a drug establishment license from Health Canada.
這是MediPharm的最新批准，繼美國食品藥品管理局、歐盟和澳大利亞TGA的GMP認證之後，MediPharm還持有加拿大衛生部頒發的藥品機構許可證。
The Toronto-based company is now positioned to produce both API and end products for Brazilian medical cannabis patients.
這家總部位於多倫多的公司現在有能力爲巴西醫用大麻患者生產原料藥和最終產品。
According to a 2023 report by industry observer Kaya Mind, the Brazilian medical cannabis market is projected to reach CA$380 million ($281.2 million) in 2025.
根據行業觀察家Kaya Mind在2023年發佈的一份報告，預計到2025年，巴西醫用大麻市場將達到3.8億加元（合2.812億美元）。
See also: New CBD & THC Cannabis Oils Now Shipping To Australia From Canada
另見：新的CBD和四氫大麻酚大麻油現已從加拿大運往澳大利亞
"This GMP certification from Brazil strengthens MediPharm's position as one of the most pharmaceutically focused medical cannabis companies in the world," said David Pidduck, MediPharm Labs CEO. Whether it is the production of cannabis-based drug research, international cannabis medical programs or future marketable cannabis drugs, MediPharm has invested in and executed the development of global pharmaceutical and medical channels.
MediPharm Labs首席執行官戴維·皮德杜克表示：“巴西的這項GMP認證鞏固了MediPharm作爲世界上最專注於製藥的醫用大麻公司之一的地位。”無論是生產以大麻爲基礎的藥物研究、國際大麻醫療項目還是未來的可銷售的大麻藥物，MediPharm都投資並執行了全球製藥和醫療渠道的開發。
MediPharm Labs currently manufactures two medical cannabis products with full ANVISA product authorization under Brazil's Resolution 327/19. Additional product authorizations are currently under review with ANVISA. In addition to existing Brazilian customers, the company entered into a supply agreement with a top-tier generic pharmaceutical company in Brazil in July 2023.
根據巴西第327/19號決議，MediPharm Labs目前生產兩種獲得ANVISA產品全面授權的醫用大麻產品。ANVISA目前正在審查其他產品授權。除了現有的巴西客戶外，該公司還於2023年7月與巴西的一家頂級仿製藥公司簽訂了供應協議。
In September 2020, MediPharm Labs confirmed a partnership with a Rio de Janeiro-based distributor. Under that deal, MedPharm Labs provides a wide range of cannabis concentrate formats for formulated products later distributed by XLR8 BRAZIL.
2020年9月，MediPharm Labs確認與一家位於里約熱內盧的分銷商建立合作伙伴關係。根據該協議，MedPharm Labs爲後來由XLR8 BRAZIL分銷的配方產品提供各種大麻濃縮物形式。
Now read: MediPharm Labs Still Hits C$8.5M Despite Sequential Drop, More On That In Q3 2023 Financial Report
立即閱讀：儘管連續下跌，但MediPharm Labs仍達到850萬加元，2023年第三季度財務報告中有更多相關信息
MEDIF Price Action
MEDIF 價格走勢
MediPharm's shares traded 2.6923% higher at $0.0534 per share after the market close on Tuesday.
週二收盤後，MediPharm的股價上漲2.6923％，至每股0.0534美元。
Benzinga Cannabis Conferences are coming to Los Angeles. Join the Benzinga Cannabis Market Spotlight: California, and unlock the future of cannabis at the premier networking event in Culver City on February 22. Connect with top industry leaders, gain insider insights into the investment landscape and shape the evolving markets in California and beyond. Don't miss this chance to be at the forefront of the cannabis industry's growth and innovation! Join now.
Benzinga大麻會議即將在洛杉磯舉行。加入 “Benzinga大麻市場聚焦：加州”，在2月22日在卡爾弗城舉行的頂級社交活動上解鎖大麻的未來。與頂級行業領導者建立聯繫，獲得對投資格局的內幕見解，塑造加利福尼亞及其他地區不斷變化的市場。千萬不要錯過這個站在大麻行業增長和創新最前沿的機會！立即加入。
譯文內容由第三人軟體翻譯。